Tenaya’s share slump following the TN-201 data drop could be due to its “significantly lower” level of RNA expression in the ...

In the LIGHTHOUSE study, Atsena Therapeutics is evaluating ATSN-201 gene therapy for X-linked retinoschisis, leveraging ...

Landmark publication in leading ophthalmology research journal demonstrates the power of 4DMT’s Therapeutic Vector Evolution platform to invent ...

Atsena Therapeutics, a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness, today announced dosing has been completed in ...

ATLANTA, GA, USA I December 11, 2024 I Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral ...

AAV = Adeno-associated virus; Ad = Adenovirus; CIA = Collagen-induced arthritis; CTLA = Cytotoxic T-lymphocyte antigen; FADD = Fas-associated death domain; FAS-L = Fas ligand; FLS = Fibroblast ...

Next-generation sequencing allows for critical insights into gene therapy products, which can help streamline and accelerate ...

02, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for ...

The investment firm said it believes TRACER alone should be a valuable asset, noting “initial novel AAV capsid candidates ...